Summary
In an attempt to reduce myeloproliferation, we administered recombinant α-2b interferon (r-αINF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-αINF was given for 16 weeks at an initial dosage of 3×106 U/day, with monthly increments in the case of response failure, i.e. a decrease in WBC or platelet count of less than 25% of the initial value. Two cases responded at the starting dosage, while the effective dosage was 5×106 U/day in the others. At the end of the 16th week, Hb showed minor changes: from an initial value of 12.08 g/dl, range 8.3–17.3, to 11.6 g/dl, range 7.7–18 (P=0.12); WBC were reduced from 54×109/l, range 6.4–69.4, to 17.5×109/l, range 5–39 (P=0.09, 4/8 responses); platelets decreased from 775×109/l, range 215–1748, to 403×109/l, range 118–730 (P=0.008, 8/8 responses). Minor changes in spleen size were also noted, while no significant changes in bone marrow fibrosis occurred. Influenza-like symptoms and fatigue were common side effects. In conclusion, r-αINF has a role as a non-leukemogenic cytoreductive agent in the therapy of MMM, especially for cases with thrombocytosis.
Similar content being viewed by others
References
Barosi G, Cazzola M, Frassoni M, Orlandi E, Stefanelli M (1981) Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics. Br J Haematol 48: 263–272
Bevan PC, Bateman CJT (1988) Interferon-alpha for idiopathic myelofibrosis. Lancet I: 766
Buyssens N, Bourgeois NH (1977) Chronic myelocytic leukemia versus idiopathic myelofibrosis: a diagnostic problem in bone marrow biopsies. Cancer 40: 1584–1561
Carlo-Stella C, Cazzola M, Gasner A (1987) Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hemopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70: 1014–1019
Dukes PP, Izadi P, Ortega JA, Shore NA, Gomperts E (1980) Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture. Exp Hematol 8: 1048–1056
Gasner A, Carlo-Stella C, Greher J, Volkers B, Hoelzer D (1987) Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 70: 1173–1179
Gastl G, Lang A, Huber Ch, Seewann H (1988) Interferonalpha for idiopathic myelofibrosis. Lancet I: 765–766
Gastl G, Aulitzky Q, Tilg H (1987) Dose related effectiveness of alpha interferon in Chronic Myelogenous Leukemia. Blut 54: 251–252
Gilbert HS (1984) Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease. In: Berk PD, Castro-Malaspina H, Wasserman LR (eds) Myelofibrosis and the biology of connective tissue. Alan R Liss, New York, pp 3–17
Gugliotta L, Macchi S, Catani L (1987) Recombinant alpha-2a interferon (αIFN) in the treatment of essential thrombocythaemia. Preliminary report. Haematologica 72: 277–279
Hasselbalch H (1988) Interferon in myelofibrosis. Lancet I: 355
Lazzarino M, Vitale A, Morra E (1987) L'interferon alfa-2b nel trattamento delle malattie mieloproliferative croniche Phl-negative con elevata trombocitosi. XXXI Congresso della Società Italiana di Ematologia, Atti 1: 101–107
Ludwig H, Linkesh W, Gisslinger H (1987) Interferon-alpha corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25: 266–273
Manoharan A (1988) Myelofibrosis: prognostic factors and treatment. Br J Haematol 69: 295–298
Parmeggiani L, Ferrant A, Bodhain JL, Sokal G (1987) Alpha-interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39: 228–232
Seewann HL, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber Ch (1988) Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56: 161–163
Talpaz M, McCredie KB, Mauligit GM, Gutterman JU (1983) Leucocyte interferon induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692
Talpaz M, Kantarijan HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematological remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Talpaz M, Mavligit GM, Keating MJ, Walters RS, Gutterman JU (1983) Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Int Med 99: 789–792
Wang JC, Lang HD (1987) Recombinant alpha interferon inhibits the proliferation of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia (MMM). Blood 70: 188a
Wickramashinghe SN, Peart S, Gill DS (1987) Alphainterferon in primary idiopathic myelofibrosis. Lancet II: 1524–1525
Wolf BC, Neiman RS (1985) Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65: 803–809
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barosi, G., Liberato, L.N., Costa, A. et al. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 58, 271–274 (1989). https://doi.org/10.1007/BF00320164
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320164